Stockscreener 앱 받기
43.52
0.07%
-0.03
시간 외 거래:
43.67
0.15
+0.34%
전일 마감가:
$43.55
열려 있는:
$44.97
하루 거래량:
9.84M
Relative Volume:
0.62
시가총액:
$192.75B
수익:
$50.91B
순이익/손실:
$18.95B
주가수익비율:
10.21
EPS:
4.261
순현금흐름:
$1.92B
1주 성능:
+1.66%
1개월 성능:
-2.73%
6개월 성능:
-8.90%
1년 성능:
-41.46%
1일 변동 폭
$43.46
$45.00
1주일 범위
$42.94
$45.00
52주 변동 폭
$35.12
$74.82
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, NVS, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
43.52 | 194.52B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,112.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.20 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.23 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.88 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.44 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-18 | 개시 | Bernstein | Outperform |
| 2026-03-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-03-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2026-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Kepler | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-12 | 업그레이드 | Jefferies | Underperform → Hold |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Novo Nordisk A/ S Stock (DK0062498333): Buyback Update Puts Capital Returns In Focus - AD HOC NEWS
Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan - Stock Titan
Novo Nordisk A/ S Stock (DK0060534915): Technical picture draws investor focus - AD HOC NEWS
Novo Nordisk A/S Stock (DK0060534915): Wegovy tablet approval and ADRs in focus after late-week gain - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Market news - investments.halifax.co.uk
Novo Nordisk Wegovy pill draws 10,000 UK waitlist ahead of approvalBloomberg - Investing.com Australia
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Weakness And GLP‑1 Growth Questions - simplywall.st
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows - Investing.com Nigeria
Novo Nordisk A/S stock (DK0062498333): Ozempic boom meets fresh obesity data and US pricing debate - AD HOC NEWS
European ADRs Started The Week In The Green - Finimize
Novo Nordisk ADR's decline widens rapidly to 3.8%, hitting a new intraday low - Bitget
Novo Nordisk stock falls on ADA conference readthrough - Investing.com
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - Sahm
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S stock (DK0062498333): Danish pharma heavyweight steadies after recent pullback - AD HOC NEWS
Novo Nordisk launches Wegovy weight-loss pill in UAE - Investing.com
Novo Nordisk Trial Updates Test Support For Obesity And Diabetes Valuation - Sahm
Novo Nordisk’s Adiposity Franchise Under Siege as CVS Levels the Playing Field and US Pricing Rule - AD HOC NEWS
Novo Nordisk Stock Forecast | Q1 Results and Guidance - Capital.com
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
US and China trade journalist expulsions in tit-for-tat moves - WPLG Local 10
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVO - TradingView
Novo Nordisk A/S (ADR) stock (DK0062498333): valuation in focus after strong run for Denmark’s pha - AD HOC NEWS
Discontinued operations of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVOC - TradingView
Total debt per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Revenue per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Book value per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVOD - TradingView
NVO News | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Total debt of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Cash Flow – BCBA:NVOD - TradingView
Book value per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Debt to equity ratio of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Average basic shares outstanding of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Net income of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.78%
0.23%
자본화:
|
볼륨(24시간):